Trial Profile

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AHB 137 (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Sponsors AusperBio

Most Recent Events

03 Oct 2025 Protocol has been amended to include one new arm (Experimental: AHB-137 (16 weeks)) , it has been changes from 2 to 3.
03 Oct 2025 Planned primary completion date changed from 2 Jun 2025 to 2 Feb 2026.
07 May 2025 Interim results presented in an AusperBio Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com